心房颤动是最常见的持续性心律失常,而心房颤动患者的脑卒中发病风险较普通人群高5倍,且病死率及致残率远高于其他原因引发的脑卒中,因此预防脑卒中是心房颤动管理的重点。华法林是过去数十年里心房颤动预防脑卒中的首选药物,但其固有的缺陷限制其在临床的广泛使用。过去几年中心房颤动的抗凝药物治疗在许多领域已经有了显著进展。现将对心房颤动血栓形成机制、目前抗凝策略及抗凝治疗进展进行综述。 Atrial fibrillation is the most common persistent arrhythmia, and stroke patients with atrial fibrillation risk of 5 times higher than the general population, and mortality and morbidity is much higher than other causes of stroke, so stroke prevention is the atrium Focused management focus. Warfarin is the drug of choice for the prevention of stroke by atrial fibrillation over the past decades, but its inherent limitations limit its widespread use in the clinic. Anticoagulation treatment of atrial fibrillation in the past few years has made significant progress in many fields. Now on the atrial fibrillation thrombosis mechanism, the current anticoagulant strategy and the progress of anticoagulant therapy are reviewed.